CytoDyn will apply for Phase 2 clinical trials of PRO140 for the treatment of colon cancer



[ad_1]

2019 ж. May 02 күні жарияланды

Nader Pourhbadan, CEO of CytoDyn Inc (OTCMKTS: CYDY), tells Proactive Investors that biotechnology has announced strong preclinical results from a series of completed studies on its treatment of colon cancer, leronlimab.

Pourhbadan says that for this reason, the company will apply to the FDA to begin Phase 2 clinical trials with PRO140 for colon cancer treatment next week.

[ad_2]
Source link